University of Calgary - Request for Proposal - DRUG FORMULATION AND DEVELOPMENT
Solicitation number AB-2024-07747
Publication date
Closing date and time 2024/09/12 07:00 EDT
Description
*Notice* Interested Proponents must download bid document from MERX www.merx.com
The University of Calgary (UCalgary) is inviting qualified, Health Canada, FDA, or equivalent certified GMP (Good Manufacturing Practices) facility Proponent(s) to submit proposals for drug development and manufacturing services to supply D-Cycloserine to be utilized for human subject usage in treating Major Depressive Disorder (the “Method of Use”) for the Mental Health Initiative for Stress and Trauma experimental study use only.
UCalgary will provide the active pharmaceutical ingredients (API’s) from a supplier with an active Drug Master File with the FDA , to the successful Proponent. UCalgary will ship the API’s in the original manufacturer’s tamper-proof packaging including the Safety Data Sheets (SDS).
Contract duration
The estimated contract period will be 36 month(s), with a proposed start date of 2024/10/07.
Trade agreements
-
No trade agreements are applicable to this solicitation process
Contact information
Contracting organization
- Organization
-
University of Calgary
- Address
-
2500 University Drive NWCalgary, CA-AB, T2N 1N4CA
- Contracting authority
- Melissa Innes
- Email
- mjinnes@ucalgary.ca
- Address
-
2500 University Dr NWCalgary, CA-AB,CA
Bidding details
Full details for this tender opportunity are available on a third-party site
Click on the button below to be directed to this website. Note that on the third-party site you may need an account to view and/or bid on this tender. Information on any fees or additional costs to access the full details is outlined in the Description tab of this tender opportunity.